As with any dietary changes, it's essential to consult with a healthcare professional for personalized advice, especially for individuals managing diabetes or other metabolic conditions
Identify treatment risks: Algorithmic checking that highlights potential drug interactions or contraindications instantly
Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide
Published January 5, 2024